Edition:
United Kingdom

Mitsubishi Tanabe Pharma updates license agreement with Kolon Life Secience on Invossa


Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Says it notified Kolon Life Secience, Inc. (KLS) that the co seeks to cancel the license agreement between the co and KLS for Invossa, a cell therapy product for improvement of knee osteoarthritis symptoms .Says it has started negotiation with KLS regarding the cancellation of the License Agreement . 

Company Quote

1254.0
-10.0 -0.79%
7:00am BST